CBIO (Crescent Biopharma) Net Margin %: -2,240.90% (As of Mar. 2026)


CBIO Crescent Biopharma Inc CBIO
10 GF Score
Price $18.56
! 2 Warning Signs
View Full Analysis

What is Crescent Biopharma Net Margin %?

Crescent Biopharma CBIO +9.24% 10 Net Margin % is -2,240.90% as of Mar. 2026. GuruFocus rates CBIO with a GF Score™ of 10/100. The stock has 2 warning signs investors should review. Among 946 Biotechnology companies, Crescent Biopharma ranks worse than 81.08% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Crescent Biopharma's Net Income for the three months ended in Mar. 2026 was $-23.28 Mil. Crescent Biopharma's Revenue for the three months ended in Mar. 2026 was $1.04 Mil. Therefore, Crescent Biopharma's net margin for the quarter that ended in Mar. 2026 was -2,240.90%.

The historical rank and industry rank for Crescent Biopharma's Net Margin % or its related term are showing as below:

CBIO' s Net Margin % Range Over the Past 10 Years
Min: -1419.61   Med: -1419.61   Max: -1363.94
Current: -1363.94

CBIO's Net Margin % is ranked worse than
81.08% of 946 companies
in the Biotechnology industry
Industry Median: -88.815 vs CBIO: -1363.94

Crescent Biopharma  (NAS:CBIO) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Crescent Biopharma Net Margin % Related Terms

Crescent Biopharma Net Margin % Historical Data

* Premium members only.

The historical data trend for Crescent Biopharma's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Crescent Biopharma Net Margin % Chart

Crescent Biopharma Annual Data
Trend Dec24 Dec25
Net Margin %
0.00 -1,419.61

Crescent Biopharma Quarterly Data
Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Net Margin % Get a 7-Day Free Trial 0.00 0.00 0.00 -852.06 -2,240.90

CBIO vs RIGL, GYRE, TRAX: Net Margin % Comparison

For the Biotechnology subindustry, Crescent Biopharma's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Crescent Biopharma Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Crescent Biopharma's Net Margin % distribution charts can be found below:

* The bar in red indicates where Crescent Biopharma's Net Margin % falls into.


CBIO
10GF Score
Crescent Biopharma Inc CBIO
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Crescent Biopharma Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Crescent Biopharma's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-153.942/10.844
=-1,419.61 %

Crescent Biopharma's Net Margin for the quarter that ended in Mar. 2026 is calculated as

Net Margin=Net Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-23.283/1.039
=-2,240.90 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of -2,240.90% mean?
Crescent Biopharma (CBIO) has a Net Margin % of -2,240.90% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Crescent Biopharma and its competitors. According to the industry distribution chart, Crescent Biopharma ranks #767 out of 946 companies in the Biotechnology industry, placing it in the top 81.1%.
Is Crescent Biopharma's Net Margin % too high?
Crescent Biopharma's current Net Margin % is -2,240.90%. Based on the distribution chart, Crescent Biopharma ranks #767 out of 946 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Crescent Biopharma has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Crescent Biopharma's Net Margin % compare to RIGL and GYRE?
According to the Biotechnology industry distribution chart, Crescent Biopharma ranks #767 out of 946 companies for Net Margin %. This places Crescent Biopharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Crescent Biopharma and its competitors. Crescent Biopharma's current Net Margin % is -2,240.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crescent Biopharma stock overvalued right now?
Crescent Biopharma (CBIO) has a current Net Margin % of -2,240.90%. The current Net Margin % is -2,240.90%. Crescent Biopharma's overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Crescent Biopharma (CBIO), the current Net Margin % is -2,240.90% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Crescent Biopharma Business Description

Other Exchanges C68:Germany
Address 300 Fifth Avenue, Waltham, MA, USA, 02451
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
10GF Score

Get the complete analysis for CBIO

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$18.56
Price